Drew W L, Miner R C, Busch D F, Follansbee S E, Gullett J, Mehalko S G, Gordon S M, Owen W F, Matthews T R, Buhles W C
Virology Research, Mount Zion Hospital and Medical Center, University of California, San Francisco 94115.
J Infect Dis. 1991 Apr;163(4):716-9. doi: 10.1093/infdis/163.4.716.
Seventy-two AIDS patients treated with ganciclovir for cytomegalovirus (CMV) disease were prospectively monitored for the development of drug-resistant virus. No resistant strains were found in 31 patients before therapy or among seven culture-positive patients treated for less than or equal to 3 months. Of 13 culture-positive patients treated for greater than or equal to 3 months, 5 excreted virus resistant (ED50, greater than 12 microM, or ED90, greater than 30 microM) to ganciclovir. Thus, 38% of patients and receiving ganciclovir for greater than 3 months and excreting virus or, overall, 7.6% of the patients were excreting CMV resistant to the drug.